Table 1 Characteristics of the study samples
| Â | Sample 1 (whole sample: DAN-MONICA, FINRISK, Moli-sani, SHHEC, Northern Sweden MONICA) | Sample 2 (sample with biomarker data available: FINRISK, Moli-sani, SHHEC, Northern Sweden MONICA) | ||||||
|---|---|---|---|---|---|---|---|---|
| Â | Overall | Diabetes | No diabetes | Missing, n (%) | Overall | Diabetes | No diabetes | Missing, n (%) |
Demographics | ||||||||
 n | 94,011 (100) | 3,834 (100) | 90,177 (100) |  | 55,271 (100) | 2,472 (100) | 52,799 (100) |  |
Cohort | ||||||||
 DAN-MONICA | 7,526 (8.0) | 178 (4.6) | 7,348 (8.1) |  |  |  |  |  |
 FINRISK | 36,907 (39.3) | 1,526 (39.8) | 35,381 (39.2) |  | 7,852 (14.2) | 397 (16.1) | 7,455 (14.1) |  |
 Moli-sani | 23,249 (24.7) | 1,468 (38.3) | 21,781 (24.2) |  | 23,198 (42.0) | 1,465 (59.3) | 21,733 (41.2) |  |
 SHHEC | 15,959 (17.0) | 276 (7.2) | 15,683 (17.4) |  | 14,190 (25.7) | 239 (9.7) | 13,951 (26.4) |  |
 Northern Sweden MONICA | 10,370 (11.0) | 386 (10.1) | 9,984 (11.1) |  | 10,031 (18.2) | 371 (15.0) | 9,660 (18.3) |  |
Women | 48,320 (51.4) | 1,771 (46.2) | 46,549 (51.6) | Â | 28,307 (51.2) | 1,066 (43.1) | 27,241 (51.6) | Â |
Age, years | 48.65 (12.5) | 57.65 (11.7) | 48.27 (12.4) | Â | 51.08 (12.2) | 60.45 (11.4) | 50.64 (12.1) | Â |
Medication | ||||||||
 Antihypertensive treatment | 13,522 (14.4) | 1,632 (42.6) | 11,890 (13.1) | 3,284 (3.5) | 9,833 (17.8) | 1,199 (48.5) | 8,634 (16.4) | 412 (0.7) |
 Lipid lowering treatment | 3,099 (3.3) | 579 (15.1) | 2,520 (2.8) | 30,281 (32.2) | 2,465 (4.5) | 479 (19.4) | 1,986 (3.8) | 15,704 (28.4) |
 Diabetes treatment | ||||||||
  Oral |  | 1,427 (37.2) |  | 810 (21.1) |  | 1,148 (46.4) |  | 518 (21.0) |
  Insulin |  | 607 (15.8) |  | 810 (21.1) |  | 388 (15.7) |  | 518 (21.0) |
  Diet |  | 990 (25.8) |  | 810 (21.1) |  | 418 (16.9) |  | 518 (21.0) |
Risk factors | ||||||||
 Alcohol use, g/d | 10.82 (18.0) | 10.60 (18.7) | 10.83 (18.0) | 2,343 (2.5) | 12.13 (19.4) | 12.41 (20.0) | 12.12 (19.4) | 1,937 (3.5) |
 BMI, kg/m2 | 26.17 (4.6) | 29.16 (5.5) | 26.05 (4.5) | 806 (0.9) | 26.61 (4.7) | 29.56 (5.5) | 26.47 (4.6) | 97 (0.2) |
 Smokers | 29,914 (31.8) | 862 (22.5) | 29,052 (32.2) | 161 (0.2) | 16,140 (29.2) | 475 (19.2) | 15,665 (29.7) | 42 (0.1) |
 Systolic BP, mmHg | 135.23 (20.6) | 145.80 (22.0) | 134.79 (20.4) | 761 (0.8) | 135.66 (20.8) | 147.42 (22.0) | 135.11 (20.6) | 15 (0.0) |
 Baseline MI | 2,194 (2.3) | 303 (7.9) | 1,891 (2.1) | 289 (0.3) | 1,450 (2.6) | 215 (8.7) | 1,235 (2.3) | 228 (0.4) |
 Baseline AF | 560 (0.6) | 51 (1.3) | 501 (0.6) | 6,328 (6.8) | 423 (0.8) | 51 (2.1) | 372 (0.7) | 6,371 (11.5) |
Biomarkers | ||||||||
 HDL, mmol/l |  |  |  |  | 1.4 (1.2 − 1.7) | 1.3 (1.1 − 1.5) | 1.4 (1.2 − 1.7) | 2996 (5.4) |
 LDL, mmol/l |  |  |  |  | 3.0 (2.4 − 3.8) | 2.9 (2.3 − 3.5) | 3.0 (2.4 − 3.8) | 3019 (5.4) |
 Triglycerides, mmol/l |  |  |  |  | 1.2 (0.9 − 1.7) | 1.4 (1.0 − 1.9) | 1.20 (0.9 − 1.6) | 2956 (5.3) |
 Insulin, pmol/l |  |  |  |  | 6.6 (4.5 − 10.0) | 9.6 (6.2 − 15.4) | 6.5 (4.4 − 9.8) | 1894 (3.4) |
 Glucose, mmol/l |  |  |  |  | 4.9 (4.5 − 5.5) | 7.3 (5.8 − 9.5) | 4.9 (4.5 − 5.4) | 3,466 (6.2) |
 Creatinine, μmol/l |  |  |  |  | 70.7 (61.9 − 79.6) | 72.5 (63.6 − 85.7) | 70.7 (61.9 − 79.6) | 1120 (2.0) |
 hs-CRP, mg/l |  |  |  |  | 1.4 (0.6 − 2.9) | 2.0 (0.9 − 4.3) | 1.3 (0.6 − 2.8) | 1109 (2.0) |
 nT-proBNP, pg/ml |  |  |  |  | 48.3 (25.5 − 90.2) | 67.1 (32.5 − 143.3) | 47.7 (25.3 − 88.1) | 6678 (12.1) |
 hs-TnI, pg/ml |  |  |  |  | 2.5 (1.4 − 4.3) | 3.2 (2.0 − 5.5) | 2.4 (1.4 − 4.2) | 2643 (4.8) |
 Vitamin D, ng/ml |  |  |  |  | 16.2 (11.5 − 22.4) | 15.3 (11.0 − 20.7) | 16.2 (11.5 − 22.4) | 2543 (4.6) |